Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM
PDF) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease Marc S. Sabatine, M.D., M.P.H., Robert P. Giugliano, M.D., Anthony C. Keech, M.D., Narimon Honarpour, M.D., Ph.D., Stephen D. Wiviott, M.D., Sabina
Repatha® Clinical Trials | Repatha® (evolocumab)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM
PCSK9 inhibitors in clinical practice: Delivering on the promise? - Atherosclerosis
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the
Managed Care Pharmacist Updates for Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) Inhibitors
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) | Journal of the American College of Cardiology
FOURIER Clinical Trial - Evolocumab and Clinical Outcomes in Patients…
![PDF] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/993698ddc1fcdfd3e66edebf1904b360eca3b4a8/6-Table2-1.png "PDF] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Semantic Scholar")
PDF] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Semantic Scholar
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM Resident 360 <meta property="twitter:image" content="https://resident360files.nejm.org/image/upload/c_fit,f_auto,h_120,w_120/v1538599218/u8buf4o8mgdxgmfcczjk.png" /> <meta ...
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects | Physiology
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM
Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization | Journal of the American College of Cardiology
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial - ScienceDirect
Abstract 13871: Evolocumab and Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: Analysis From FOURIER | Circulation
NEJM on Twitter: "Original Article: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER) https://t.co/XorSjqmvoy #ACC17 https://t.co/wzFxrdlbzn" / Twitter
Repatha® Clinical Trials | Repatha® (evolocumab)
PCSK9 inhibitor evolocumab cuts risk of cardiovascular events, study results show - The Pharmaceutical Journal
FOURIER - Evolocumab in patients with CVD — NERDCAT
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects | Physiology
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia | Journal of the American College of Cardiology
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia - ScienceDirect
Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl | PLOS ONE
FOURIER Clinical Trial - Evolocumab and Clinical Outcomes in Patients…
Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention - Clinical Therapeutics
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM
